LOT YPB.238✓ COA VERIFIED
✓ Purity ≥ 98%Research use only
2X Blend CJC-1295 Without DAC / Ipamorelin
Bundle & save
Certificate of Analysis — Lot YPB.238
View COABlend information
What's inside
2 compounds per vial
2X Blend CJC-1295 Without DAC5 mg
Ipamorelin5 mg
Storage requirements
Stability information
Protect from lightRoom-temp stable (short-term)
Lyophilized (powder)−20°C · stable long-term
Reconstituted2–8°C · use within 30 days
Lab verification
Verified by a third-party lab
This lotYPB.238
Each componentTested ✓
TestedDec 2025 · USA
Result6 of 6 tests passed
Research overview
2X Blend CJC-1295 Without DAC / Ipamorelin in the literature
Contents 2X Blend (CJC-1295 without DAC + Ipamorelin) Form / storage Lyophilized powder; store at −20 °C, protect from light Purity Per-component assay — see lot COA Testing Per-component assay, heavy metals, microbial (TAMC/TYMC) COA Batch-specific — view on this page Research background This blend combines two complementary secretagogues acting on distinct receptors of the somatotropic axis: CJC-1295 without DAC engages the GHRH receptor, while Ipamorelin selectively agonizes the ghrelin/GHS-R1a receptor. The pairing is widely used as a model for studying how simultaneous GHRH-receptor and ghrelin-receptor stimulation interact. Co-administration of a GHRH analog with a ghrelin-receptor agonist has been of interest because the two pathways are reported to produce additive or synergistic effects on GH release in preclinical studies. Research applications Dual-pathway model for GHRH-receptor and GHS-R1a co-stimulation Tool combination for additive/synergistic secretagogue signaling Reference blend for comparison vs. single peptides Quality & documentation Every lot is tested by an independent third-party laboratory before it enters the catalog. Blends report a per-component quantitative assay (content vs. label claim) rather than a single purity figure, plus heavy-metal and microbial screening.
HighlightsCo-administration of a GHRH analog with a ghrelin-receptor agonist has been of interest because the two pathways are reported to produce additive or synergistic effects on GH release in preclinical studies.Research applications Dual-pathway model for GHRH-receptor and GHS-R1a co-stimulation Tool combination for additive/synergistic secretagogue signaling Reference blend for comparison vs.single peptides Quality & documentation Every lot is tested by an independent third-party laboratory before it enters the catalog.Blends report a per-component quantitative assay (content vs.
COA breakdown
✓ 6 of 6 tests passedPASSIdentityλ-max matchesLambda-max vs reference standardPASSPurity≥98% · UV/VisUV/Vis correlationPASSQuantitative assay≥95% of labelBeer-Lambert · ≥95% label claimPASSHeavy metals<20 ppbNMT 150 ppb/vial specPASSTAMC · aerobic microbial0 CFUNMT 1,000 CFU · 48 h @ 37 °CPASSTYMC · yeast & mold0 CFUNMT 100 CFU · 48 h @ 30 °C
Purity is measured per lot; panel results per the Analytical Formulations summary report for the lot currently shipping.
Product details
- Type
- Research peptide
- Form
- Lyophilized powder
- Storage
- Room temp in transit · −20 °C long-term
